Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2015, Article ID 810942, 4 pages
http://dx.doi.org/10.1155/2015/810942
Research Article

An Evaluation of the Correlation between Hepcidin Serum Levels and Disease Activity in Inflammatory Bowel Disease

Department of Gastroenterology, Izmir Katip Çelebi University, İzmir Atatürk Eğitim ve Araştırma Hastanesi, Karabağlar, 35160 İzmir, Turkey

Received 19 September 2014; Accepted 2 December 2014

Academic Editor: Andrew Thillainayagam

Copyright © 2015 Zehra Betül Paköz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Stein, F. Hartmann, and A. U. Dignass, “Diagnosis and management of iron deficiency anemia in patients with IBD,” Nature Reviews Gastroenterology and Hepatology, vol. 7, no. 11, pp. 599–610, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. N. Zhao, A.-S. Zhang, and C. A. Enns, “Iron regulation by hepcidin,” The Journal of Clinical Investigation, vol. 123, no. 6, pp. 2337–2343, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. J.-C. Deschemin and S. Vaulont, “Role of hepcidin in the setting of hypoferremia during acute inflammation,” PLoS ONE, vol. 8, no. 4, Article ID e61050, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. J. L. Babitt, F. W. Huang, D. M. Wrighting et al., “Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression,” Nature Genetics, vol. 38, no. 5, pp. 531–539, 2006. View at Publisher · View at Google Scholar · View at PubMed
  5. D. M. Wrighting and N. C. Andrews, “Interleukin-6 induces hepcidin expression through STAT3,” Blood, vol. 108, no. 9, pp. 3204–3209, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. M. S. Silverberg, J. Satsangi, T. Ahmad et al., “Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology,” The Canadian Journal of Gastroenterology, vol. 19, supplement A, pp. 5A–36A, 2005. View at Google Scholar
  7. K. W. Schroeder, W. J. Tremaine, and D. M. Ilstrup, “Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study,” The New England Journal of Medicine, vol. 317, no. 26, pp. 1625–1629, 1987. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. G. D'Haens, W. J. Sandborn, B. G. Feagan et al., “A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis,” Gastroenterology, vol. 132, no. 2, pp. 763–786, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. M. Arabul, M. Celik, O. Aslan et al., “Hepcidin as a predictor of disease severity in acute pancreatitis: a single center prospective study,” Hepato-Gastroenterology, vol. 60, no. 123, pp. 595–600, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. M. A. Abdel-Khalek, A. M. El-Barbary, S. A.-M. Essa, and A. S. Ghobashi, “Serum hepcidin: a direct link between anemia of inflammation and coronary artery atherosclerosis in patients with rheumatoid arthritis,” The Journal of Rheumatology, vol. 38, no. 10, pp. 2153–2159, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. R. J. Basseri, E. Nemeth, M. E. Vassilaki et al., “Hepcidin is a key mediator of anemia of inflammation in Crohn's disease,” Journal of Crohn's & Colitis, vol. 7, no. 8, pp. e286–e291, 2013. View at Publisher · View at Google Scholar · View at PubMed
  12. J. Arnold, A. Sangwaiya, B. Bhatkal, F. Geoghegan, and M. Busbridge, “Hepcidin and inflammatory bowel disease: dual role in host defence and iron homoeostasis,” European Journal of Gastroenterology & Hepatology, vol. 21, no. 4, pp. 425–429, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. P. Oustamanolakis, I. E. Koutroubakis, I. Messaritakis, N. Malliaraki, A. Sfiridaki, and E. A. Kouroumalis, “Serum hepcidin and prohepcidin concentrations in inflammatory bowel disease,” European Journal of Gastroenterology and Hepatology, vol. 23, no. 3, pp. 262–268, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. L. Wang, E. Trebicka, Y. Fu et al., “The bone morphogenetic protein-hepcidin axis as a therapeutic target in inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 18, no. 1, pp. 112–119, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. J. Nagy, L. Lakner, V. S. Poór et al., “Serum prohepcidin levels in chronic inflammatory bowel diseases,” Journal of Crohn's and Colitis, vol. 4, no. 6, pp. 649–653, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. G. Semrin, D. S. Fishman, A. Bousvaros et al., “Impaired intestinal iron absorption in Crohn's disease correlates with disease activity and markers of inflammation,” Inflammatory Bowel Diseases, vol. 12, no. 12, pp. 1101–1106, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus